BR112021019901A2 - Método para tratar síndrome de abstinência neonatal devido à retirada de opioides - Google Patents

Método para tratar síndrome de abstinência neonatal devido à retirada de opioides

Info

Publication number
BR112021019901A2
BR112021019901A2 BR112021019901A BR112021019901A BR112021019901A2 BR 112021019901 A2 BR112021019901 A2 BR 112021019901A2 BR 112021019901 A BR112021019901 A BR 112021019901A BR 112021019901 A BR112021019901 A BR 112021019901A BR 112021019901 A2 BR112021019901 A2 BR 112021019901A2
Authority
BR
Brazil
Prior art keywords
withdrawal
syndrome due
opioid
treat neonatal
treat
Prior art date
Application number
BR112021019901A
Other languages
English (en)
Inventor
Massimo Cella
Ann Thomson Merran
Karl Kraft Walter
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of BR112021019901A2 publication Critical patent/BR112021019901A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

método para tratar síndrome de abstinência neonatal devido à retirada de opioides. a presente invenção refere-se a formulações compreendendo buprenorfina que são úteis para tratar síndrome de abstinência devido à retirada de opioides.
BR112021019901A 2019-04-18 2020-04-17 Método para tratar síndrome de abstinência neonatal devido à retirada de opioides BR112021019901A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835711P 2019-04-18 2019-04-18
PCT/EP2020/060811 WO2020212549A1 (en) 2019-04-18 2020-04-17 Method for treating neonatal opiod withdrawal syndrome

Publications (1)

Publication Number Publication Date
BR112021019901A2 true BR112021019901A2 (pt) 2022-02-15

Family

ID=70470980

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019901A BR112021019901A2 (pt) 2019-04-18 2020-04-17 Método para tratar síndrome de abstinência neonatal devido à retirada de opioides

Country Status (11)

Country Link
US (1) US20200330455A1 (pt)
EP (1) EP3955888A1 (pt)
JP (1) JP2022529773A (pt)
KR (1) KR20220003541A (pt)
CN (1) CN114007587A (pt)
AU (1) AU2020259128A1 (pt)
BR (1) BR112021019901A2 (pt)
CA (1) CA3136028A1 (pt)
MA (1) MA55719A (pt)
MX (1) MX2021012577A (pt)
WO (1) WO2020212549A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023003810A1 (en) * 2021-07-18 2023-01-26 Case Western Reserve University Compositions and methods for treating opioid dependence and withdrawal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
EP1897543A1 (en) * 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
PL2915525T3 (pl) * 2011-09-19 2022-01-17 Orexo Ab Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson
WO2016105563A1 (en) * 2014-12-23 2016-06-30 Arx, Llc Method of producing uniform buprenorphine-containing formulations
EP3697381B1 (en) * 2017-10-20 2023-06-07 Chiesi Farmaceutici S.p.A. Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof

Also Published As

Publication number Publication date
EP3955888A1 (en) 2022-02-23
WO2020212549A1 (en) 2020-10-22
US20200330455A1 (en) 2020-10-22
JP2022529773A (ja) 2022-06-24
MX2021012577A (es) 2021-11-12
CN114007587A (zh) 2022-02-01
MA55719A (fr) 2022-02-23
KR20220003541A (ko) 2022-01-10
CA3136028A1 (en) 2020-10-22
AU2020259128A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CL2020001852A1 (es) Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066)
BR112018013065A2 (pt) composições e métodos para o tratamento de hemoglobinopatias
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
WO2017106957A8 (en) Lipid-linked prodrugs
BR112018004620A2 (pt) moduladores da expressão de kras
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
BR112017021167A2 (pt) composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
BR112018011709A2 (pt) inibidores bicíclicos de pad4
UY36357A (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa))
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
MA55193A (fr) Procédés de préparation d'un inhibiteur de pi3k
BR112018015836A2 (pt) administração de células t engenheiradas para tratamento de cânceres no sistema nervoso central
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
BR112016026544A2 (pt) métodos para inibir a necroptose
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2019002190A (es) Uso de pridopidina para tratar distonías.
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
CY1125201T1 (el) Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma)
BR112018007517A2 (pt) métodos para tratar esclerose múltipla usando compostos de pirimidina e piridina com atividade inibidora de btk
BR112018000481A2 (pt) ?processos para preparação de compostos e de (-)-ambrox (v)?